PIK3CA and neoplasm: In the BOLERO-2 study, PIK3CA mutation analysis in archival tumour samples of 302 patients has revealed that median PFS was longer for wild-type PIK3CA carriers in both treatment arms (Hortobagyi et al. 2016).